The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors.
L. E. Strong
Employment or Leadership Position - Quintessence Biosciences
Stock Ownership - Quintessence Biosciences (B)
J. A. Kink
Employment or Leadership Position - Quintessence Biosciences
B. Mei
Employment or Leadership Position - Quintessence Biosciences
M. N. Shahan
Employment or Leadership Position - Quintessence Biosciences
R. T. Raines
Consultant or Advisory Role - Quintessence Biosciences (B)
Stock Ownership - Quintessence Biosciences (B)